Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 11/20 | 0.46 |
| ▸ | HTR3A | P46098 | 10/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.41 |
| ▸ | HTR3B | O95264 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.41 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5404570 | 0.95 | CHRNA7 (0.43) | CHRNA7HTR3AGAASMN1; SMN2MEN1 | |
| SCHEMBL5403328 | 0.91 | HTR3A (0.42) | CHRNA7HTR3AGAASMN1; SMN2TSHR | |
| Hydrochloric Acid SCHEMBL5651641 | 0.89 | HTR3A (0.41) | CHRNA7HTR3AGAASMN1; SMN2MEN1 | |
| Fumaric Acid SCHEMBL5420260 | 0.84 | CHRNA7 (0.43) | CHRNA7HTR3AHTR3EHTR3BALOX15 | |
| Fumaric Acid SCHEMBL5420255 | 0.84 | CHRNA7 (0.43) | CHRNA7HTR3AHTR3EHTR3BALOX15 | |
| SCHEMBL1542568 | 0.82 | HTR3A (0.46) | CHRNA7HTR3AGAASMN1; SMN2MEN1 | |
| SCHEMBL13444722 | 0.81 | CHRNA7 (0.59) | CHRNA7HTR3AGAA | |
| SCHEMBL3928547 | 0.81 | CHRNA7 (0.59) | CHRNA7HTR3AGAA | |
| Hydrochloric Acid SCHEMBL5649732 | 0.81 | HTR3A (0.44) | CHRNA7HTR3AGAASMN1; SMN2MEN1 | |
| SCHEMBL5400969 | 0.81 | CHRNA7 (0.55) | CHRNA7HTR3AGAASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2681221-B1 | TRICYCLIC INHIBITORS OF KINASES | ABBVIE INC (US) | 2016-05-18 | — | — | EP | disclosed |
| US-8710065-B2 | Tricyclic inhibitors of kinases | ABBVIE INC. (US) | 2014-04-29 | — | — | US | disclosed |
| EP-2681221-A1 | TRICYCLIC INHIBITORS OF KINASES | AbbVie Inc. (US) | 2014-01-08 | — | — | EP | disclosed |
| WO-2012161812-A1 | TRICYCLIC INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-11-29 | — | — | WO | disclosed |
| US-20120220572-A1 | TRICYCLIC INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220572-A1 | TRICYCLIC INHIBITORS OF KINASES | WEE1, WEE2, CDK1 | CHRNA7 4589/4885HTR3A 3111/4885GAA 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.